中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

109 records (took 0.077 seconds)

    Tissue plasminogen activator having zymogenic or fibrin specific properties
    13.
    发明授权
    Tissue plasminogen activator having zymogenic or fibrin specific properties 失效
    组织纤溶酶原激活剂具有酶原或纤维蛋白特异性

    公开(公告)号：US5405771A

    公开(公告)日：1995-04-11

    申请号：US178945

    申请日：1994-01-07

    Applicant: Stephen Anderson ,  William F. Bennett ,  David Botstein ,  Deborah L. Higgins ,  Nicholas F. Paoni ,  Mark J. Zoller

    Inventor： Stephen Anderson ,  William F. Bennett ,  David Botstein ,  Deborah L. Higgins ,  Nicholas F. Paoni ,  Mark J. Zoller

    IPC: A61K38/00 ,  A61K38/48 ,  C07H21/04 ,  C12N1/21 ,  C12N5/10 ,  C12N9/64 ,  C12N9/72 ,  C12N15/55 ,  C12N15/58 ,  C12N15/63 ,  C12N15/70 ,  C12N15/86

    CPC classification number: C12N9/6456 ,  A61K38/00

    Abstract: Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.

    Abstract translation: 制备组织纤溶酶原激活剂（t-PA）酶原和变体，包括t-PA的纤维蛋白溶解活性变体，其在t-PA的蛋白酶结构域内的位置具有氨基酸改变，与相应的野生型t- PA，与相应的野生型t-PA相比，其改变使纤维蛋白溶酶原纤维蛋白原和/或纤维蛋白（或血浆凝块）存在下的变形酶原。 可以制备编码酶原和变体的DNA序列，以及掺入DNA序列的表达载体和用表达载体转化的宿主细胞。 酶原和变体可用于药物制剂中以治疗血管疾病或病症或预防纤维蛋白沉积或哺乳动物中的粘附形成或重新形成。

    Rennin-containing disrupted yeast cells used in cheese manufacture
    14.
    发明授权
    Rennin-containing disrupted yeast cells used in cheese manufacture 失效
    含有Rennin的干酪生产中使用的破碎的酵母细胞

    公开(公告)号：US4695470A

    公开(公告)日：1987-09-22

    申请号：US471360

    申请日：1983-02-28

    Applicant: David Botstein ,  Gerald R. Fink ,  Ronald W. Davis

    Inventor： David Botstein ,  Gerald R. Fink ,  Ronald W. Davis

    IPC: A23C19/032 ,  C12N9/64 ,  A23C9/12

    CPC classification number: C12N9/6481 ,  A23C19/0325

    Abstract: Yeast cells that express rennin or prorennin are used in disrupted cellular form to clot milk without the need for purification of the rennin or prorennin. Cheese making is simplified and reduced in cost by the avoidance of substantial purification techniques to obtain rennin or prorennin from living cells which produce these materials.

    Abstract translation: 表达rennin或prorennin的酵母细胞以破碎的细胞形式使用，不需要纯化肾素或肾上腺素就能凝固牛奶。 通过避免实质的纯化技术从生产这些材料的活细胞中获得肾素或凝血酶原，可以简化和降低成本。

    FGF-19 NUCLEIC ACIDS
    15.
    发明申请
    FGF-19 NUCLEIC ACIDS 审中-公开
    FGF-19核酸

    公开(公告)号：US20110207912A1

    公开(公告)日：2011-08-25

    申请号：US13013734

    申请日：2011-01-25

    Applicant: David Botstein ,  Audrey Goddard ,  Austin L. Gurney ,  Kenneth J. Hillan ,  David A. Lawrence ,  Margaret Ann Roy

    Inventor： David Botstein ,  Audrey Goddard ,  Austin L. Gurney ,  Kenneth J. Hillan ,  David A. Lawrence ,  Margaret Ann Roy

    IPC: C07K14/50 ,  C07H21/04 ,  C12N15/63 ,  C12N1/19 ,  C12P21/02 ,  C12N5/10 ,  C12N1/21

    CPC classification number: C07K14/50 ,  C07K2317/24 ,  C07K2319/00

    Abstract: The present invention is directed to novel polypeptides having homology to the PRO533 protein and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention. The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based on the identification of genes that are amplified in the genome of tumor cells. Such gene amplification is expected to be associated with the overexpression of the gene product and contribute to tumorigenesis and/or autocrine signaling. Accordingly, the proteins encoded by the amplified genes are believed to be useful targets for the diagnosis and/or treatment (including prevention) of certain cancers, and may act of predictors of the prognosis of tumor treatment. Furthermore, the compounds, compositions including antagonists and methods of the present invention are further expected to have therapeutic effect upon conditions characterized by FgF-19 modulation.

    Abstract translation: 本发明涉及与PRO533蛋白质和编码这些多肽的核酸分子具有同源性的新型多肽。 本文还提供了包含那些核酸序列的载体和宿主细胞，包含与异源多肽序列融合的本发明多肽的嵌合多肽分子，与本发明的多肽结合的抗体，以及本发明多肽的制备方法 发明。 本发明涉及用于诊断和治疗哺乳动物包括人类的肿瘤细胞生长和增殖的组合物和方法。 本发明基于在肿瘤细胞基因组中扩增的基因的鉴定。 预期这种基因扩增与基因产物的过度表达有关，并且有助于肿瘤发生和/或自分泌信号传导。 因此，由扩增的基因编码的蛋白质被认为是某些癌症的诊断和/或治疗（包括预防）的有用靶标，并且可以作为肿瘤治疗预后的预测因子。 此外，进一步预期本发明的化合物，包括拮抗剂和方法的组合物对于以FgF-19调节为特征的病症具有治疗作用。

Patent Agency Ranking